Acticor Biotech S.A.S. (7V7)

Overview

Acticor Biotech SAS, a clinical stage biopharmaceutical company established in 2013, dedicates itself to the development of innovative treatments targeting acute thrombotic diseases. The company, with its foundation in Paris, France, is at the forefront of designing therapeutic solutions that address significant medical needs within this domain. Acticor Biotech’s approach to tackling these health challenges involves a focus on the development of its flagship product, glenzocimab, alongside actively engaging in strategic collaborations, such as the one with the University of Birmingham. These partnerships are aimed at bolstering the company's research and development efforts, particularly in the execution of clinical trials vital for assessing the efficacy and safety of their novel treatments.

Products and Services

Acticor Biotech SAS is devoted to the innovation and development of treatments that offer hope to patients suffering from acute thrombotic diseases. Below is an outline of their primary product and its current developmental standings:

• Glenzocimab: This humanized monoclonal antibody fragment is designed to target platelet glycoprotein VI. Its primary objective is to prevent the progression of thrombosis without the risk of bleeding often associated with antiplatelet drugs. Glenzocimab is under rigorous clinical examination, with several significant milestones achieved in its development journey:
  • Phase 2/3 Clinical Trial for Acute Ischemic Stroke: Glenzocimab has reached Phase 2/3 in its clinical trial phase for the treatment of acute ischemic stroke, underlining its potential as a critical therapeutic option for this sudden and severe condition.
  • Completed Phase 1b/2a Clinical Trial: The drug has successfully completed Phase 1b/2a clinical trials, further affirming its safety profile and providing valuable insights into its pharmacodynamic parameters in the context of acute ischemic stroke.
  • Phase 2/3 Clinical Trial for Cerebrovascular Accidents in Emergency Situations: Acticor is also exploring glenzocimab’s effectiveness in treating cerebrovascular accidents, commonly known as strokes, in emergency settings, demonstrating the company’s commitment to expanding the therapeutic applications of glenzocimab.
  • Completed Phase 2 Clinical Trial for Treating Acute Respiratory Distress Syndrome (COVID-19): Acknowledging the link between thrombosis and COVID-19 complications, glenzocimab has been tested in a Phase 2 clinical trial for its ability to treat acute respiratory distress syndrome caused by COVID-19, showcasing the versatility and potential of Acticor's pioneering product.

In addition to its product development, Acticor Biotech SAS engages in strategic collaborations to enhance the breadth and depth of its research endeavors. Notably, the collaboration agreement with the University of Birmingham for Phase 2b clinical trials of glenzocimab in treating heart attacks underscores the company’s proactive approach in forging partnerships to advance its therapeutic offerings.